Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AZN
AZN logo

AZN News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

AZN News

MindWalk Files European Patent for Biological Data Architecture Underpinning AI Drug Discovery

1d agoPRnewswire

MindWalk Files European Patent for Biological Data Architecture Underpinning AI Drug Discovery

1d agoNewsfilter

US Stocks Rise on Tech Bargain Hunting and Optimism for Rate Cuts

2d agoseekingalpha

Comparative Analysis of International Stock ETFs

5d agoNASDAQ.COM

Comparison of Core International Stock ETFs

5d agoFool

AstraZeneca Partners with CSPC for $1.77B Kidney Disease Treatments

5d agoseekingalpha

Abbisko and AstraZeneca Collaborate on Novel Lung Cancer Therapy

5d agoNASDAQ.COM

Abbisko and AstraZeneca Form Strategic Collaboration for Lung Cancer Therapy

5d agoseekingalpha

AZN Events

07/01 21:30
Abbisko and AstraZeneca Enter Strategic Collaboration
Abbisko Therapeutics announced that it has entered into a strategic collaboration agreement with AstraZeneca to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer. As a multicenter, open-label Phase I/II clinical study, the combination will evaluate the safety and efficacy of Abbisko's first-in-class oral small-molecule PD-L1 inhibitor, lumipodlin, in combination with AstraZeneca's third-generation EGFR-TKI, TAGRISSO, for the treatment of patients with EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC. On May 20, 2026, the investigational new drug application for the combination study was cleared by the National Medical Products Administration. This Phase II study will be led by Abbisko, and both Abbisko and AstraZeneca will share responsibilities for the clinical trial.
06/30 14:00
AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this daily recap compiled by The Fly.NEW UNIT:Francessca Vasquez, Vice President of Frontier AI Engineering and Services, AWS, said in a blog post, "I'm excited to announce that we are meeting that demand by creating a dedicated AWS Forward Deployed Engineering organization. Backed by a $1B investment, the AWS FDE model is different in three key ways: it is agentic-first, it compresses timelines from months to days, and it is designed so customers are self-sufficient when a deployment ends. AWS FDE embeds AWS frontier teams-working with purpose-built agents-directly inside customer teams. These experienced engineers, many of whom build our AWS AI services, partner with a customer's business, engineering, and security teams to build and deploy production AI systems with their data, governance, and processes. Unlike traditional consulting that assesses, recommends, and treats each deployment as a standalone project, AWS FDE builds for the long term. Customers leave AWS FDE deployments with both new solutions and new engineering capabilities. Along with agentic systems running in their own AWS environment, they gain lasting AI skills, workflows, and patterns they can use to innovate independently. Deployments are structured around shared goals and business results, not billable hours. When customers succeed, we succeed."CLAUDE SCIENCE:Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang. Publicly traded companies in the pharmaceutical space include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.CLAUDE APPS GETAWAY:Anthropic introduced the Claude apps gateway for Amazon Bedrock and Google Cloud. Previously, running Claude Code on these platforms has meant provisioning a cloud credential per developer, manually pushing settings to every laptop, and standing up separate tooling to see per-developer spend. The gateway is a self-hosted control plane that gives you corporate SSO login, centrally enforced policy, role-based access, and per-user cost attribution for Claude Code. The gateway is run as a single stateless container deployed on Linux and backed by a PostgreSQL database. It holds your upstream credential, authenticates developers against your identity provider, distributes and enforces managed settings, and reports per-user usage to a collector you operate. Onboarding a developer means adding them to your Identity Provider. Offboarding means removing them.Meanwhile, Anthropic said that, starting Monday, Claude models are generally available in MicrosoftFoundry, hosted on Azure. "Claude runs in your Azure environment with the authentication, billing, and governance controls your teams already use," Anthropic said. "You can choose where inference is processed, including a US data zone for teams with data residency requirements. Anthropic operates the inference and is the data processor."
06/30 13:30
Anthropic Launches Claude Science for Scientific Research
Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a broader push to become a major platform in biology and life sciences backed by rapidly growing scale and financial resources comparable to leading drug companies, STAT's Matthew Herper and Brittany Trang report. Publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

AZN Monitor News

AstraZeneca Partners with Abbisko for Lung Cancer Therapy

Jul 02 2026

AstraZeneca's IMFINZI Approved for Bladder Cancer Treatment

Jun 01 2026

AstraZeneca's tozorakimab shows success in COPD trials

Mar 27 2026

AstraZeneca Expands R&D Operations in China

Mar 20 2026

AstraZeneca Awards $3.4 Million to Nonprofits for Health Equity Initiatives

Feb 11 2026

AstraZeneca Raises FY 2026 Revenue Guidance Amid Strong Q4 Results

Feb 10 2026

AstraZeneca's DATROWAY Receives FDA Priority Review for TNBC

Feb 06 2026

AstraZeneca to Invest $15 Billion in China and Partner with CSPC

Feb 02 2026

AZN Earnings Analysis

No Data

No Data

People Also Watch